Ebos Group Limited · NZX:EBO
Ebos — UBS Australasia Conference 2015
15 slides from Ebos's conference presentation, Nov 17, 2015
Slide 1: UBS Australasia Conference
For personal use only UBS Australasia Conference John Cullity – CFO EBOS Group Ltd 17 November 2015 1
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliabil
Slide 3: Introduction
Introduction For personal use only If you needed access to medicine in either Australia or New Zealand over the past year – whether through your local pharmacy, in a hospital, an aged care facility or even for your pet through a vet – it’s likely EBOS played a vital role in getting that medicine to
Slide 4: EBOS Group – Snapshot
EBOS Group – Snapshot For personal use only EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care products marketer and distributor. 1 # combined pharmacy and
Slide 5: EBOS Group Overview
EBOS Group Overview Trans-Tasman Healthcare and Animal Care portfolio For personal use only ~$2.0 billion 42 market capitalisation locations in Australia Dual listed on NZX and ASX and New Zealand $6.1 billion 2,400+ FY15 revenue employees Australia 78%, NZ 22% $196.7 million 38,000+ FY15 EBITDA cus
Slide 6: EBOS Group Overview – Market channels
EBOS Group Overview – Market channels For personal use only HEALTHCARE ANIMAL CARE Community Pharmacy Institutional Healthcare Contract Logistics Pet Care and Veterinary Pharmacy Wholesale Product Pharmacy Services Pharmacy Retail Retail Consumer Products Wholesale EBOS is the trusted partner to gov
Slide 7: Strong Financial Results in FY15
Strong Financial Results in FY15 For personal use only $m $m +7.2% +14.2% constant constant currency currency $m $m +16.9% +17.2% constant currency 7
Slide 8: Cash Flow and Net Debt
Cash Flow and Net Debt EBOS has an excellent portfolio of strong cash generating businesses For personal use only • Focus on tight working capital NZ$m FY15 FY14 Var$ Var% management led to record Operating EBITDA 196.7 175.4 21.3 12.1% cash flow of $133.8m being generated Interest paid (21.9) (27.1
Slide 9: M&A Update - Red Seal Acquisition – Nov'2015
M&A Update - Red Seal Acquisition – 16 Nov’2015 For personal use only • EBOS has entered into an agreement to acquire Red Seal for NZD$80 million. • Red Seal is a leading New Zealand natural health products business and has experienced significant growth in export markets, particularly in China. It
Slide 10: Red Seal Product Categories
Red Seal Product Categories For personal use only Vitamins, minerals, Herbal, fruit and Non-fluoride Functional foods Agency supplements green teas toothpastes and other 10
Slide 11: M&A Update - Zest Acquisition – October 2015
M&A Update - Zest Acquisition – 30 October 2015 For personal use only • EBOS has recently acquired Zest as part of the Company’s expanding presence in the delivery and administration of specialty pharmaceutical products. • ZEST is a leading healthcare communications business with extensive experienc
Slide 12: FY16 Trading Update – excluding recent acquisitions
FY16 Trading Update – excluding recent acquisitions For personal use only • We have made a positive start to the new financial year with growth in profit in the first quarter consistent with the performance we delivered in the second half of FY15. This is driven in part by the contribution of the ac
Slide 13: EBOS strategy
EBOS strategy For personal use only • Protect and grow our market leading positions in pharmacy in both New Zealand and Australia – across wholesale, consumer products and pharmacy retail • Pursue further growth in the institutional Continue disciplined focus on healthcare market appropriately price
Slide 14: Track record of delivering shareholder value
Track record of delivering shareholder value For personal use only Earnings Per Share (cents) Dividends Per Share (cents) * 80.0 50.0 47.0 70.8 45.0 41.0 70.0 62.8 40.0 60.0 53.6 34.0 35.0 32.5 31.0 31.5 50.0 45.4 46.8 41.8 30.0 41.1 39.5 25.0 37.6 23.0 40.0 32.5 25.0 21.5 22.5 22.5 31.7 30.0 20.0 1
Slide 15: Track record of delivering shareholder value
Track record of delivering shareholder value For personal use only 14.00 Share Price (NZ$) 12.00 +189.4% (excluding dividends) 10.00 8.00 6.00 +18.9% 10 year compound annual return (including dividends) 4.00 2.00 31-Oct-05 31-Oct-06 31-Oct-07 31-Oct-08 31-Oct-09 31-Oct-10 31-Oct-11 31-Oct-12 31-Oct-